BEDFORD, Ohio, Aug. 28 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., has announced that it will begin marketing Ciprofloxacin Injection USP as of August 28, 2006. This product is AP rated and is equivalent to Cipro I.V. (R) by Bayer. Ciprofloxacin Injection USP is a synthetic broad-spectrum antimicrobial agent that is indicated in the prevention or treatment of infections that are proven or strongly suspected to be caused by bacteria.
“As part of our objective to offer an extensive selection of products to meet the changing needs of healthcare professionals, we are pleased to announce the addition of Ciprofloxacin Injection USP to our portfolio,” said David Gaugh, General Manager of Bedford Laboratories.
Bedford Laboratories will supply Ciprofloxacin Injection USP as a single dose vial in two presentations: 200mg in a 20mL vial and 400mg in a 40mL vial.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department, (800) 521-5169, or from the company’s web site, http://www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and approximately 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion (9.5 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information please visit http://www.boehringer-ingelheim.com
Ben Venue Laboratories Inc.
CONTACT: Natalie Haynes, 1-800-562-4797, ext. 3592, for Ben VenueLaboratories Inc.
